Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2019 | IVLBCL: a retrospective study

Tycel Phillips • 3 Jun 2019
ASCO 2019
Diffuse Large B-Cell Lymphoma Lymphoma

Tycel Phillips, MD, of the University of Michigan, Ann Arbor, MI, discusses a study investigating how outcomes have changed for intravascular large B-cell lymphoma (IVLBCL), a rare kind of diffuse large B-cell lymphoma (DLBCL). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Tycel Phillips

Retrospective study on outcomes and safety of covalent BTK inhibitors for the treatment of MCL
2:32
Retrospective study on outcomes and safety of covalent BTK inhibitors for the treatment of MCL
Tycel Phillips • 6 Dec 2025
Interim analysis of a Phase II study of the GLOVe regimen in untreated, high-risk MCL
3:24
Interim analysis of a Phase II study of the GLOVe regimen in untreated, high-risk MCL
Tycel Phillips • 6 Dec 2025
Long-term disease control associated with epcoritamab and CAR T-cell therapy in LBCL
2:15
Long-term disease control associated with epcoritamab and CAR T-cell therapy in LBCL
Tycel Phillips • 6 Dec 2025
The evolving paradigm of frontline DLBCL treatment: strategies being explored in trial
1:50
The evolving paradigm of frontline DLBCL treatment: strategies being explored in trial
Tycel Phillips • 6 Dec 2025

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Tycel Phillips • 6 Dec 2025
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
2:10
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
Tycel Phillips • 8 Dec 2025
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
2:42
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
Tycel Phillips • 8 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Tycel Phillips • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals